At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,018 enrolled
Drug / intervention
Ferric Carboxymaltose +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
In Brief
A Phase 3 clinical trial evaluating Ferric Carboxymaltose and Standard Medical Care (SMC) for Anemia. Completed, enrolled 2,018 participants across 1 site.
Detailed Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionMar 2009
Study CompletionJul 2009
TodayJul 2026
First PostedOct 24, 2007
Enrollment StartOct 1, 2007
Primary CompletionMar 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.7 years ago
Interventions
Ferric Carboxymaltosedrug
Standard Medical Care (SMC)drug